The study examined the role of soluble E-cadherin (sE-cad) levels in patients with newly diagnosed non-small cell lung cancer (NSCLC) compared to healthy individuals.
There was a significant increase in sE-cad levels in NSCLC patients, which was linked to the development of distant metastases and poorer patient outcomes.
While the findings indicate that sE-cad could be a potential prognostic biomarker for NSCLC, it was not proven to be an independent factor for survival in this analysis.